

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

JAN 17 2002

Sheet

1

of

Application Number	09/648,864
Filing Date	August 25, 2000
First Named Inventor	Howard M. Johnson
Group Art Unit	1646
Examiner Name	Janet Andres, Ph.D.
Attorney Docket Number	UF-243X

TECH CENTER 1000/2000

FEB 04 2002

RECEIVED

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>JH</i>	R1	DUSHEIKO, G. M. et al. "Recombinant Leucocyte Interferon Treatment of Chronic Hepatitis B" <i>Journal of Hepatology</i> , 1986, pp. S199-S207, Vol. 3 (Suppl. 2), Elsevier Science Publishers Biomedical Division.
	R2	KHAN, O. A. et al. "Immunomodulating Functions of Recombinant Ovine Interferon Tau: Potential for Therapy in Multiple Sclerosis and Autoimmune Disorders" <i>Multiple Sclerosis</i> , 1998, pp. 63-69, Vol. 4, Stockton Press.
	R3	KIMATA, H. et al. "Interferon-Alpha Treatment for Severe Atopic Dermatitis" <i>Allergy</i> , 1995, pp. 837-840, Vol. 50.
↓	R4	NOH, G. W. and LEE, K. Y. "Blood Eosinophils and Serum IgE as Predictors for Prognosis of Interferon-gamma Therapy in Atopic Dermatitis" <i>Allergy</i> , 1998, pp. 1202-1207, Vol. 53.
	R5	
	R6	
	R7	
	R8	
	R9	
	R10	
	R11	
	R12	
	R13	

Examiner Signature

Janet Andres

Date Considered

10/17/02

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.